648 related articles for article (PubMed ID: 34126053)
1. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.
Bauer A; Schreinlechner M; Sappler N; Dolejsi T; Tilg H; Aulinger BA; Weiss G; Bellmann-Weiler R; Adolf C; Wolf D; Pirklbauer M; Graziadei I; Gänzer H; von Bary C; May AE; Wöll E; von Scheidt W; Rassaf T; Duerschmied D; Brenner C; Kääb S; Metzler B; Joannidis M; Kain HU; Kaiser N; Schwinger R; Witzenbichler B; Alber H; Straube F; Hartmann N; Achenbach S; von Bergwelt-Baildon M; von Stülpnagel L; Schoenherr S; Forer L; Embacher-Aichhorn S; Mansmann U; Rizas KD; Massberg S;
Lancet Respir Med; 2021 Aug; 9(8):863-872. PubMed ID: 34126053
[TBL] [Abstract][Full Text] [Related]
2. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Cohen JB; Hanff TC; William P; Sweitzer N; Rosado-Santander NR; Medina C; Rodriguez-Mori JE; Renna N; Chang TI; Corrales-Medina V; Andrade-Villanueva JF; Barbagelata A; Cristodulo-Cortez R; Díaz-Cucho OA; Spaak J; Alfonso CE; Valdivia-Vega R; Villavicencio-Carranza M; Ayala-García RJ; Castro-Callirgos CA; González-Hernández LA; Bernales-Salas EF; Coacalla-Guerra JC; Salinas-Herrera CD; Nicolosi L; Basconcel M; Byrd JB; Sharkoski T; Bendezú-Huasasquiche LE; Chittams J; Edmonston DL; Vasquez CR; Chirinos JA
Lancet Respir Med; 2021 Mar; 9(3):275-284. PubMed ID: 33422263
[TBL] [Abstract][Full Text] [Related]
3. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
[TBL] [Abstract][Full Text] [Related]
4. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
5. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.
Cohen JB; Hanff TC; Corrales-Medina V; William P; Renna N; Rosado-Santander NR; Rodriguez-Mori JE; Spaak J; Andrade-Villanueva J; Chang TI; Barbagelata A; Alfonso CE; Bernales-Salas E; Coacalla J; Castro-Callirgos CA; Tupayachi-Venero KE; Medina C; Valdivia R; Villavicencio M; Vasquez CR; Harhay MO; Chittams J; Sharkoski T; Byrd JB; Edmonston DL; Sweitzer N; Chirinos JA
J Clin Hypertens (Greenwich); 2020 Oct; 22(10):1780-1788. PubMed ID: 32937008
[TBL] [Abstract][Full Text] [Related]
6. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
7. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Koshy AN; Murphy AC; Farouque O; Ramchand J; Burrell LM; Yudi MB
Intern Med J; 2020 Dec; 50(12):1468-1474. PubMed ID: 33191600
[TBL] [Abstract][Full Text] [Related]
9. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
11. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.
Bhandari S; Mehta S; Khwaja A; Cleland JGF; Ives N; Brettell E; Chadburn M; Cockwell P;
N Engl J Med; 2022 Dec; 387(22):2021-2032. PubMed ID: 36326117
[TBL] [Abstract][Full Text] [Related]
12. Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).
Legrand M; Futier E; Leone M; Deniau B; Mebazaa A; Plaud B; Coriat P; Rossignol P; Vicaut E; Gayat E;
Trials; 2019 Mar; 20(1):160. PubMed ID: 30836981
[TBL] [Abstract][Full Text] [Related]
13. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
14. The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial.
Misra S; Parida S; Sahajanandan R; Behera BK; Senthilnathan M; Mariappan R; Chandy TT;
Trials; 2022 Aug; 23(1):670. PubMed ID: 35978368
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
16. RAS inhibition and COVID-19: more questions than answers?
Kerneis M; Montalescot G
Lancet Respir Med; 2021 Aug; 9(8):807-809. PubMed ID: 34126055
[No Abstract] [Full Text] [Related]
17. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis.
Chambergo-Michilot D; Runzer-Colmenares FM; Segura-Saldaña PA
High Blood Press Cardiovasc Prev; 2023 May; 30(3):265-279. PubMed ID: 37171528
[TBL] [Abstract][Full Text] [Related]
19. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Hakeam HA; Alsemari M; Duhailib ZA; Ghonem L; Alharbi SA; Almutairy E; Sheraim NMB; Alsalhi M; Alhijji A; AlQahtani S; Khalid M; Barry M
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):244-252. PubMed ID: 33231487
[TBL] [Abstract][Full Text] [Related]
20. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
